$1.08
-0.02 (-1.82%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CELZ is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 observational · 1 expanded access
Held by 1 tracked-famous manager (Hudson Bay Capital Management LP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Project PHOENIX: Molecular Signatures of Burn Pit ExposureNCT07562243observationalDifferential gene expression (RNA-seq normalized counts) between burn pit-exposed and unexposed cohorts | — | Not yet recruiting | Other: Prior Burn Pit Exposure, No Known Burn Pit Exposure | Burn Pit Exposure, Airborne Hazard Exposure, Veteran Health, Deployment-Related Toxic Exposure, Biomarkers, Immune Dysfunction, Respiratory Symptoms | 1,000 | 2029-05-01 | in 986 d | 2026-05-01 |
| Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesNCT05626712Number of Participants with Adverse EventsRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Biological: CELZ-201 Administration · Other: Control Group | Type 1 Diabetes, Diabetes Mellitus, Type 1 | 18 | 2027-01-31 | in 165 d | 2026-02-19 |
| Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back PainNCT06053242Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.Randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: CELZ-201-DDT · Other: Placebo | Chronic Low-back Pain, Degenerative Disc Disease | 45 | 2026-05-01 | — | 2026-02-13 |
| CELZ-201-DDT for the Treatment of Chronic Lower Back PainNCT07137559expanded access | — | Available | Drug: CELZ-201-DDT | Chronic Back Pain, Degenerative Disc Disease Lumbar | — | — | — | 2025-08-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19